Mandate

Vinge advises Industrifonden on the investment in Aprea AB

November 07, 2007

Vinge advises Industrifonden on its investment in Aprea AB, a pharmaceutical company that develops and carries out research on a new drug against cancer. Aprea will raise MSEK 50 through this share issue of which Industrifonden contributes with MSEK 25 and will thereby become a new owner in the company.

Industrifonden is represented by partner Johan Winnerblad with assistance from Johan Larsson.

Related

Vinge advises Sveafastigheter on the establishment of its EMTN programme and issuance of EUR 300 million bonds

Vinge has advised Sveafastigheter AB (publ) as Swedish legal counsel on the establishment of a euro medium-term note programme (the “EMTN programme”) with a framework of EUR 2 billion and the issuance of senior unsecured bonds totalling EUR 300 million under the EMTN programme.
January 23, 2026

Vinge advises EQT AB on its combination with Coller Capital

Vinge advises EQT AB on its acquisition Coller Capital, a global secondaries firm with nearly USD 50 billion in total assets under management across institutional, private wealth and insurance-related capital.
January 22, 2026

Vinge advises Nordic Re-Finance AB on a Swedish railway financing

Vinge has acted as Swedish legal counsel to Nordic Re-Finance AB, a leading lessor of locomotives for rail freight traffic in Scandinavia, in connection with the execution of a EUR 250m debt package fully underwritten by Natixis CIB.
January 21, 2026